GlassScriptPhysician profile
Maitri Kalra
NPI 1457615270
$3,257.43
in general payments reported to CMS, 2019-2025
14 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $116 · 2021: $27.35 · 2022: $167 · 2023: $425 · 2024: $2,135 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,856 · Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,856.25 |
| Food and Beverage | $955.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,997.19 | 2024 | |
| Gilead Sciences, INC. | $431.22 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $404.10 | 2022-2024 | Tecentriq, Phesgo, Itovebi |
| Amgen INC. | $99.95 | 2019 | |
| Rigel Pharmaceuticals, INC. | $75.00 | 2020 | |
| Janssen Biotech, INC. | $49.78 | 2020-2022 | |
| Caris Mpi, INC. | $46.20 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $38.10 | 2020-2023 | Lynparza, Keytruda |
| Daiichi Sankyo INC. | $37.42 | 2022-2024 | Enhertu |
| Lilly USA, LLC | $28.03 | 2023 | Jaypirca, Retevmo, Verzenio |
| Novocure INC. | $21.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.43 | 2021 | |
| Kite Pharma, INC. | $13.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maitri Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.